Table 1.
Stage and type of bias | Strategy implemented |
Protocol development | |
Design bias | Extensive international scientific, clinical and ethical input on the protocol; patient and family input to refine the patient-important bleeding outcome |
Corporate conflicts of interest | Peer-review funded trial; locally sourced pantoprazole |
Procedural bias | Standard operating procedures guide protocol implementation; central statistical monitoring is ongoing throughout the trial |
Omission bias | Eligibility criteria are broad; enrolment is in five continents |
Surveillance bias | Rigorous training of research personnel |
Detection of ventilator-associated pneumonia (VAP) | To avoid biased choice of VAP definition: VAP reporting has one main and several alternate definitions |
Protocol implementation | |
Prognostic imbalance | At point of randomisation, patients are stratified for prehospital acid suppression which may influence outcomes |
Selection bias | Allocation is concealed; research personnel screening, consenting, and enrolling patients are unaware of randomisation sequence |
Detection and performance bias | Patients, families, all clinical and research personnel are blinded |
Measurement bias | Primary efficacy outcome: Clinically important GI bleeding is centrally adjudicated by two physicians trained in study procedures, and blinded to allocation and centre |
Loss to follow-up | Primary Safety Outcome: for 90-day mortality status, multiple methods used for patients discharged alive before 90 days; all other outcomes are hospital based as recorded in medical charts |
Missing data | Each research record is reviewed and validated at least three times by Methods Center staff |
Analysis | |
False claims of benefit | A priori statistical approach is very conservative for stopping early for apparent benefit before full sample size reached |
False claims of no difference | A priori statistical approach does not include stopping early for futility before full sample size reached |
Confirmation bias | Analyst is blinded to allocation until after the final analysis |
Analytic bias | Analysis will adhere to the intention-to-treat principle |
Dissemination | |
Reporting bias | Trial reporting will adhere to trial registration (NCT03374800), protocol and statistical analysis plan |
Publication bias | Results will be disseminated through many knowledge translation strategies including peer-review journals |
These are the strategies we protocolised to minimise bias in four different phases of the trial.